| Recruiting | Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous | Phase 2 | 2025-03-27 |
| Recruiting | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head a Head and Neck Squamous Cell Carcinoma | Phase 3 | 2024-09-25 |
| Recruiting | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma | Phase 3 | 2024-06-25 |
| Terminated | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer | Phase 2 | 2022-11-17 |
| Active Not Recruiting | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2021-04-28 |
| Completed | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult | Phase 1 | 2019-05-08 |
| Recruiting | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer | Phase 1 / Phase 2 | 2018-05-02 |
| Completed | MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. Breast Cancer Metastatic | Phase 2 | 2018-01-15 |
| Terminated | MCLA-117 in Acute Myelogenous Leukemia Acute Myelogenous Leukemia, Acute Myeloid Leukemia | Phase 1 | 2016-04-01 |
| Approved For Marketing | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusio NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer | — | — |